Phosphatidylserine TSE/BSE Statement Review for European Buyers

European phosphatidylserine buyers often clear the obvious commercial questions first: source, assay, MOQ, packaging, specification, COA path, and novel-food fit. Then a downstream quality or customer questionnaire raises a narrower but very real issue: do we have a usable TSE/BSE statement for this exact phosphatidylserine route, and is it strong enough for the stage we are trying to approve?

The short answer is that a phosphatidylserine TSE/BSE review should be handled as a route-specific animal-origin and document-control task, not as a vague reassurance. The European Commission explains that TSEs include diseases such as BSE in cattle and scrapie in small ruminants, and that Regulation (EC) No 999/2001 forms the legal basis for almost all EU legislative action on TSEs. The Commission also explains that public-health requirements for the entry into the Union of products of animal origin include Regulation (EC) No 999/2001, while imported products of animal origin present a high level of risk and undergo specific checks at EU border control. The practical implication is an inference from those primary sources: if a phosphatidylserine route is being presented as plant-derived and outside an animal-origin import-control path, the buyer still needs a controlled statement that matches the exact route under quotation rather than a casual email.

That distinction matters because European buyers do not ask for a TSE/BSE statement only when they suspect a problem. They ask because customer files, internal QA questionnaires, distributor approval packs, and contract-manufacturer reviews often require a clear answer on animal-origin risk and statement scope. A generic note saying "plant source" may help early commercial discussion. It does not automatically answer whether the exact route under review has been documented clearly enough for a Europe-facing supplier file.

This article is written for ingredient importers, distributors, supplement manufacturers, private-label brands, procurement managers, quality teams, and regulatory reviewers serving Europe. It focuses on supplier qualification, controlled statement review, and first-order readiness. It does not provide legal advice and it does not make medical treatment claims.

Nutranexa가 언급되는 경우에는 검증된 현장 사실만을 사용합니다. 현재 부지는 운영 회사가 2013년에 설립된 산둥 백안루이 바이오제약유한회사로 식별되며, 110,000+ m2 규모의 캠퍼스를 운영하며 주로 유럽과 북미를 대상으로 합니다. 또한 포스파티딜세린, 대두 유래 포스파티딜세린, 그리고 해바라기 유래 포스파티딜세린 on separate buyer paths, alongside 품질 및 연구개발, 제조, 그리고 영업팀 연락처 pages for current document requests. Final approval should still depend on the exact route, the current controlled statement, and the buyer’s own Europe-facing review path.

구매자가 먼저 알아야 할 간단한 답변

If your team is reviewing a phosphatidylserine TSE/BSE statement for Europe, the minimum workable process is:

1. 정확한 경로를 먼저 고정하세요: 일반 PS, 콩 PS, 또는 해바라기 PS.
2. Confirm whether the question is about animal-origin status, customer questionnaire support, or first-order supplier approval.
3. Review the current TSE/BSE statement together with the route description, current specification, and source file.
4. Escalate anything that goes beyond a simple route declaration before the answer becomes a customer-facing promise.
5. Record a clear go, hold, or escalation decision.

That is the practical distinction buyers often miss. A statement can be commercially useful without being complete for every stage. A general product page can help orient the route. A sample COA can show batch-reporting style. None of those items, by itself, proves that the exact phosphatidylserine route has a controlled TSE/BSE answer that matches the current Europe-facing file.

Why TSE/BSE Statement Review Is Its Own Buyer Task

EU TSE controls focus on animal-origin risk, not casual product nicknames

The official EU sources frame TSE/BSE controls around animal-origin risk. The Commission’s TSE page explains that Regulation (EC) No 999/2001 is the legal basis for almost all legislative actions on TSEs and that the rules cover trade in live animals and products of animal origin. The Commission’s page on products of animal origin for human consumption separately lists Regulation (EC) No 999/2001 among the public-health requirements that apply to entry into the Union for those products. Another Commission page on official controls states that imported products of animal origin present a high level of risk and therefore undergo specific checks.

For phosphatidylserine buyers, that does not mean every route automatically falls into an animal-origin import framework. It means the buyer should stop answering TSE/BSE questions with a nickname such as "PS powder" or "sunflower route" and start answering them with a controlled route-specific document. If the commercial file is presenting a route as plant-derived, the statement should make that route clear enough that procurement, QA, and customer-facing teams are not forced to infer the answer.

The business lesson is simple: a TSE/BSE statement is not usually requested because the buyer believes phosphatidylserine is an animal-origin product. It is requested because the buyer needs a formal answer showing how the route should be classified and reviewed inside the approval file.

Plant-derived commercial routes still need controlled document answers

This is where many teams become careless. They correctly understand that a soy-derived or sunflower-derived route is not the same thing as a bovine or ovine product. Then they assume no further statement control is needed.

That shortcut causes downstream friction because European approval files often ask a more exact question:

That is why TSE/BSE review belongs beside, not inside, the other statement reviews. 알레르기 진술서 검토 answers a source and allergen-control question. GMO 진술서 검토 answers a traceability and declaration question. Novel-food review for EU buyers answers a route authorization question. TSE/BSE review answers a narrower but separate question: how should the animal-origin risk position for this exact phosphatidylserine route be documented?

The Six-Part Buyer Workflow for Phosphatidylserine TSE/BSE Review

정확한 포스파티딜세린 경로와 상업 단계를 먼저 확정하세요

Before requesting or approving any TSE/BSE statement, fix the commercial route in writing. Is the team reviewing general phosphatidylserine as an early comparison, or one source-specific route such as soy PS or sunflower PS? Is the statement needed for shortlist qualification, quotation approval, contract-manufacturer onboarding, distributor resale, or first bulk order?

This matters because TSE/BSE questions quickly become vague when the route is moving. A salesperson may send a general PS document. QA may be reviewing a soy-route file. The customer may be asking about sunflower because the non-soy position is commercially attractive. If the route is not fixed first, the statement review becomes a filing exercise instead of a control exercise.

오프닝 음은 보통 다음과 같이 기록되어야 합니다:

• 정확한 제품 경로
• 유럽을 향한 사용 의도
• 상업 무대
• 이미 서류가 준비되어 있습니다
• specific TSE/BSE or animal-origin question still open

That note prevents the team from asking for one statement and applying it to several different route discussions.

Separate route identity from the customer’s animal-origin concern

The second step is to identify what the downstream party is actually asking.

Sometimes the customer wants a simple animal-origin declaration for supplier qualification. Sometimes QA needs a controlled TSE/BSE-free statement in the technical file. Sometimes a contract manufacturer wants confirmation that the route under review is plant-derived before it aligns the broader compliance pack.

Those are related questions, but they are not identical. The buyer should separate:

1. 그 노선 being quoted
2. 그 document type being requested
3. 그 상업 무대 at which the answer will be used

That separation keeps the review practical. A shortlist-stage distributor may only need confirmation that the supplier can issue the right route-specific statement. A first-order or customer-dossier stage may require a current formal statement plus matching source and specification files. Without that distinction, teams overpromise early and underdocument later.

Review the TSE/BSE statement, specification, and source file together

This is the control point that saves time later. Buyers should not review the TSE/BSE statement in isolation. They should compare it directly against the route description, current specification, and related source file.

At minimum, the review should ask:

That comparison matters because a TSE/BSE statement often fails for one simple reason: it belongs to a broader product family while the commercial file has already narrowed into a specific route. A buyer should not assume the route match is obvious. It should be checked deliberately.

This is also where the current Nutranexa structure helps. Buyers can compare 포스파티딜세린, 대두 유래 포스파티딜세린, 그리고 해바라기 유래 포스파티딜세린 separately, then align the statement request with 구매자가 PS 재료에 대해 어떤 서류를 요청해야 할까요? 그리고 포스파티딜세린 공급업체 온보딩 so the route and file set stay synchronized.

Escalate route or process questions before they become customer promises

Not every TSE/BSE question can be closed at procurement level. Some should be escalated immediately.

보통 다음과 같은 상황에서 상황을 강화하는 것이 적절합니다:

• the commercial route changed after the original statement was collected
• the statement is generic while the customer is asking for a route-specific answer
• the file does not clearly distinguish between a general plant-source claim and a formal TSE/BSE declaration
• the buyer is being asked to answer process or material questions not covered by the current controlled file
• a downstream customer wants to reuse the statement in a way that exceeds the current approval stage

The right escalation note does not need to be dramatic. It should simply state:

1. which route is under review
2. what question remains open
3. which file is missing or unclear
4. who owns the next answer

That is far safer than letting sales or procurement translate a generic statement into a more specific customer promise than the file actually supports.

Keep TSE/BSE review separate from novel-food, allergen, and GMO files

One reason these files drift is that teams treat every compliance question as if it were interchangeable. It is not.

That separation is commercially useful because it prevents a customer questionnaire from being answered with whichever file happens to be easiest to find. The stronger workflow is to map each question to one controlled document type, then close it clearly.

마무리하려면 go, hold, 또는 에스컬레이션 결정으로

The last step is to record an outcome another team can use:

• 시작: the route, statement, and supporting file are aligned well enough for the current stage.
• 홀드: the route may still be commercially attractive, but the current statement or route match is not controlled enough yet.
• 에스컬레이션: the question goes beyond the current file and needs technical, quality, or customer-specific review.

This final note matters because TSE/BSE questions often resurface late. The quote is moving, the customer wants a document pack, and QA realizes nobody wrote down whether the current statement actually belongs to the route under approval. One short closeout note prevents that avoidable loop.

Need a Current TSE/BSE Support File for a Europe Project?

If your team is still relying on one generic animal-origin email while comparing soy and sunflower phosphatidylserine routes, pause before the quotation becomes a customer-facing commitment. Use Nutranexa’s 연락처 페이지 검토 중인 정확한 포스파티딜세린 경로에 대한 현재 경로별 명문 경로, 명세 경로 및 관련 소스 지원 파일을 요청하기 위해.

The fastest inquiries usually include the route, intended Europe use, order stage, expected quantity, and whether the question is being raised by procurement, QA, a contract manufacturer, or a downstream customer.

Common Mistakes in Phosphatidylserine TSE/BSE Review

Most failures come from file-control mistakes rather than from the existence of the question itself.

1. Asking for a general TSE/BSE statement before the team has fixed whether it is approving soy PS, sunflower PS, or only a general PS benchmark.
2. Treating a plant-source product nickname as if it automatically answers a controlled animal-origin question.
3. Using a COA or product page in place of a current route-specific statement.
4. Letting a customer questionnaire turn a generic statement into a more specific promise than the controlled file supports.
5. Mixing TSE/BSE review with allergen, GMO, or novel-food files and assuming one of them can stand in for the others.
6. Closing the commercial file without recording a go, hold, or escalation decision.

실질적인 해결책은 좁고 반복 가능한 것입니다: 복습의 중심에 한 가지 질문을 두세요. What controlled TSE/BSE or animal-origin statement do we need for this exact phosphatidylserine route at this exact Europe-facing stage?

검증된 Nutranexa 사실이 이 워크플로우에 어떻게 적합한가

For buyers evaluating Nutranexa, several verified site facts support a cleaner TSE/BSE statement workflow.

첫째, 부지는 이미 분리되어 있습니다 포스파티딜세린, 대두 유래 포스파티딜세린, 그리고 해바라기 유래 포스파티딜세린 into distinct buyer paths. That helps teams keep the statement attached to one stable commercial route instead of one vague “PS” category.

Second, the site confirms usable supplier baseline facts for qualification: the company was founded in 2013, operates a 110,000+ m2 campus, and primarily serves Europe and North America. Those facts help orient the supplier file before the buyer requests route-specific statements.

Third, Nutranexa’s public site provides request paths through 품질 및 연구개발, 제조, 그리고 영업팀 연락처 rather than implying that one public marketing file answers every controlled question. That is the right operating pattern for TSE/BSE review as well: the buyer should request the current route-specific statement file and align it with the commercial stage.

넷째, 사이트는 포스파티딜세린에 대한 검증된 기초 처리 사실을 제공하며, 여기에는 25kg MOQ 그리고 드럼당 25kg 그물 packaging, together with visible COA/specification evidence and factory, packaging, and dispatch context. Those facts help first-order planning, but they do not replace the route-specific statement review described in this article.

출처

• European Commission: Control of TSEs (including BSE and scrapie)
• European Commission: Products of Animal Origin for Human Consumption
• European Commission: Animals and Products of Animal Origin
• Regulation (EC) No 999/2001
• European Commission: Animal By-Products
• Regulation (EC) No 1069/2009

자주 묻는 질문

Do European buyers need a TSE/BSE statement for phosphatidylserine?

Often yes, as a supplier-qualification or customer-file document. The practical need is usually not because buyers think phosphatidylserine is automatically an animal-origin product, but because they need a controlled statement showing how the exact route should be documented.

Is a phosphatidylserine COA enough for TSE/BSE review?

No. A COA can show reporting style or batch information, but it does not replace a route-specific TSE/BSE or animal-origin statement.

Should a soy phosphatidylserine statement and a sunflower phosphatidylserine statement be treated as interchangeable?

No. Buyers should match the statement to the exact route under quotation and not assume one route document automatically covers another route.

What is the most common TSE/BSE workflow mistake?

Approving a generic statement before fixing the exact route and commercial stage. That usually leads to a mismatch between the statement, the specification, and the customer question being answered.

What should buyers request from Nutranexa if the TSE/BSE file is still unclear?

Request the exact route-specific statement path, the current specification path, and the related source-support files for the phosphatidylserine route under review, then align them to the commercial stage before approval.

결론

Phosphatidylserine TSE/BSE review becomes manageable when buyers stop treating it as a vague reassurance and start treating it as a route-specific document-control task.

The strongest Europe-facing workflow is practical: lock the route first, identify what the downstream party is really asking, review the statement together with the specification and source file, escalate anything that exceeds the current controlled answer, and close with a clear commercial decision. That approach helps ingredient buyers avoid a common qualification failure: the project is moving, the customer question has arrived, but no one can clearly show that the TSE/BSE statement in the file belongs to the exact phosphatidylserine route being approved.

추천 다음 단계

• 검토 포스파티딜세린 제품 페이지.
• 비교 두두 PS 그리고 선바라기 PS.
• 체크 제조 증명 그리고 품질 및 연구개발.